We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.
- Authors
Le, Thuc M.; Poddar, Soumya; Capri, Joseph R.; Abt, Evan R.; Woosuk Kim; Liu Wei; Uong, Nhu T.; Cheng, Chloe M.; Braas, Daniel; Nikanjam, Mina; Rix, Peter; Merkurjev, Daria; Zaretsky, Jesse; Kornblum, Harley I.; Ribas, Antoni; Herschman, Harvey R.; Whitelegge, Julian; Faull, Kym F.; Donahue, Timothy R.; Czernin, Johannes
- Abstract
Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phosphoproteomic approaches, we show that inhibition of the replication stress sensing kinase ataxia telangiectasia and Rad3-related protein (ATR) reduces the output of both de novo and salvage pathways by regulating the activity of their respective rate-limiting enzymes, ribonucleotide reductase (RNR) and deoxycytidine kinase (dCK), via distinct molecular mechanisms. Quantification of nucleotide biosynthesis in ATR-inhibited acute lymphoblastic leukemia (ALL) cells reveals substantial remaining de novo and salvage activities, and could not eliminate the disease in vivo. However, targeting these remaining activities with RNR and dCK inhibitors triggers lethal replication stress in vitro and long-term disease-free survival in mice with B-ALL, without detectable toxicity. Thus the functional interplay between alternative nucleotide biosynthetic routes and ATR provides therapeutic opportunities in leukemia and potentially other cancers.
- Subjects
LEUKEMIA; RIBONUCLEOSIDE diphosphate reductase; LYMPHOBLASTIC leukemia; ATAXIA telangiectasia; ACUTE leukemia
- Publication
Nature Communications, 2017, Vol 8, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-017-00221-3